Solid-state battery technology company QuantumScape Co. (NYSE: QS) stock awakened, jumping nearly 46% on news of a new agreement with PowerCo, a subsidiary of Volkswagen AG (OTCMKTS: VWAGY). QuantumScape received much hype and fanfare in 2021 regarding its solid-state lithium-metal battery techn.... |
Good MorningEquity markets tried to build on the previous week's strength, but the gains were fleeting. The S&P 500 closed with a small daily gain but aligned with recent highs. The move suggests a lack of momentum and increasing resistance to higher prices that may cap gains for the remainder of the summer. The CPI report was good but aligned with the outlook for FOMC rate cuts that are already priced into the market. There is a high risk that it will be a sell-the-news event, and a stock market price correction will soon follow.
The S&P 500 may not fall far. The outlook for earnings growth remains robust, and with interest rates set to drop, strength will bleed into a broader array of sectors. In this scenario, a market correction is a buy-the-dip opportunity leading to another multi-quarter rally for the index. Featured: The 7 Stocks Quietly Gaining Attention Right Now (Ad) 
| Consumer Discretionary | |
Solid-state battery technology company QuantumScape Co. (NYSE: QS) stock awakened, jumping nearly 46% on news of a new agreement with PowerCo, a subsidiary of Volkswagen AG (OTCMKTS: VWAGY). QuantumScape received much hype and fanfare in 2021 regarding its solid-state lithium-metal battery techn... Read the Full Story |
| From Our Partners | | Tobacco, telecom, pipelines, and healthcare real estate trade at 10 to 15 times earnings while the index yields about 1 percent.
A free report highlights seven cash-generating stocks with a 5 percent forward yield floor and roughly 6.5 percent average cash yield, capped at two picks per sector.
Each pick includes coverage numbers and an honest bear case. Five of the seven have raised payouts for 17 to 56 straight years. | | Get the seven high-yield dividend stocks free now |
| Technology | |
NVIDIA Corp. (NASDAQ: NVDA) continues to be one of the best-performing stocks in 2024. At a split-adjusted price of $129.71, NVDA stock is up 160% in 2024. However, NVIDIA’s coattails appear to be fairly short. The market growth is limited to a relatively narrow range of stocks, mostly in la... Read the Full Story |
| Consumer Discretionary | |
Ford Motor Company (NYSE: F) is navigating a significant transformation as the automotive sector transitions from gas power and embraces the electric vehicle (EV) future. This shift has led many investors and Ford Motor’s analyst community to wonder if now is the time to buy Ford Motor sto... Read the Full Story |
| From Our Partners | | More than 25 candidates were screened for share price between $1 and $5, market cap above $100 million, daily volume over 500,000 shares, and over $10 million in trailing revenue.
Only five stocks cleared every filter, spanning five different sectors. Two are profitable today, and one pays a substantial dividend.
The report also flags what could go wrong with each pick, including dilution and convertible debt. | | See the five stocks that survived this strict revenue screen |
| Industrials | |
The iShares Russell 2000 ETF (NYSE: IWM) experienced a significant breakout above multi-year resistance last week, sparked by the release of the CPI inflation data on Thursday. This move was one of the most eye-opening events of the week, drawing significant attention to small-cap stocks.
IWM's I... Read the Full Story |
| Markets | |
International Gaming Technology PLC (NYSE: IGT) provides worldwide electronic gambling, gaming, and lottery products and services. It’s well known for providing most of the slot machines in Las Vegas in the pre-pandemic era. The company has expanded to include digital games through its Pla... Read the Full Story |
| From Our Partners | | Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies.
Dr. Mark Skousen, who met Musk in person and called the SpaceX listing months early, says he has identified all three targets in what he calls Elon's $2.1 Trillion Hit List.
See the three companies before the rumors become headlines. | | Get the details on all three companies now |
| Finance | |
The insurance industry is being rattled by fintech disruptors like Lemonade Inc. (NYSE: LMND). Critics will say that underwriting policies are an art form and that human actuaries and adjusters can’t be replaced by artificial intelligence (AI). Insurance policies are best drawn up face-to-... Read the Full Story |
| Consumer Staples | |
It’s no secret that most of the market’s attention has been centered around the technology sector, especially in stocks dealing with the advancement and global adoption of artificial intelligence, names like NVIDIA Co. (NASDAQ: NVDA) and even Taiwan Semiconductor Manufacturing (NYSE: T... Read the Full Story |
| Consumer Staples | |
Fabless semiconductor developer Advanced Micro Devices Inc. (NASDAQ: AMD) stock had been largely unresponsive during the artificial intelligence (AI) boom as its shares peaked at $227.30 on March 8, 2024. On the other hand, rival NVIDIA Co. (NASDAQ: NVDA) has taken all the spotlight, hitting all... Read the Full Story |
| Consumer Discretionary | |
The June CPI was much better than expected and has the broad market set up to rally over the next six to 12 months. The rally is driven by the expectation for FOMC interest rate cuts, which will reduce the cost of money and reinvigorate the bull market, assuming no recession unfolds. While most st... Read the Full Story |
| Consumer Discretionary | |
As the dominant eCommerce giant, Alibaba Group Holding Ltd. (NYSE: BABA) is often considered the Amazon.com Inc. (NASDAQ: AMZN) of China. By sales, it's the third largest eCommerce giant in the world. With shares trading up just 3.6% year-to-date (YTD), it is also considerably underperforming th... Read the Full Story |
| Tuesday's Early Bird Stock Of The Day Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. | Should I Buy Alnylam Pharmaceuticals Stock? ALNY Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Alnylam Pharmaceuticals was last updated on Monday, October 12, 2026 at 7:57 PM.
Alnylam Pharmaceuticals Bull Case -
Alnylam Pharmaceuticals, Inc. recently reported strong financial performance in its most recent quarter, with revenue of $1.29 billion, representing a 66.9% year-over-year increase, and earnings per share of $1.84, which exceeded the consensus estimate of $1.63 by $0.21, demonstrating robust commercial execution and profitability with a net margin of 15.26%.
-
The stock currently trades at $227.02, which is significantly below the consensus price target of $366.65, suggesting substantial potential upside of approximately 61% for investors, supported by a "Moderate Buy" consensus rating from analysts who view the current valuation as attractive relative to the company's growth trajectory.
-
Alnylam Pharmaceuticals, Inc. maintains a diversified portfolio of commercial RNAi therapies, including ONPATTRO, GIVLAARI, OXLUMO, and AMVUTTRA, which address rare diseases with high unmet medical needs, providing a stable revenue base while the company continues to develop next-generation treatments for conditions such as hypertension and Alzheimer's disease.
-
Recent analyst actions, including an upgrade to a "strong-buy" rating by Zacks Research and a "buy" rating from HC Wainwright with a $455.00 price target, indicate growing institutional confidence in the company's ability to capitalize on its RNA interference platform and expand its market share in the biopharmaceutical sector.
-
The company exhibits strong balance sheet health with a current ratio of 3.05 and a quick ratio of 2.99, indicating ample liquidity to fund ongoing research and development initiatives and strategic collaborations with partners such as Regeneron and Roche, which may lead to future revenue streams from licensed products.
Alnylam Pharmaceuticals Bear Case -
Alnylam Pharmaceuticals, Inc. is facing ongoing securities fraud investigations by multiple law firms, including Glancy Prongay Wolke & Rotter LLP and The Law Offices of Frank R. Cruz, which allege possible violations of federal securities laws, posing significant legal and reputational risks that could impact shareholder value and lead to costly litigation.
-
The stock has experienced a significant decline from its 52-week high of $495.55 to the current price of $227.02, reflecting a drop of over 54%, which may indicate broader market concerns about the company's valuation, competitive positioning, or the sustainability of its recent revenue growth rates.
-
Short interest in Alnylam Pharmaceuticals, Inc. has increased to 7,711,495 shares as of September 30, 2026, representing a 7.19% month-over-month increase, suggesting that a growing number of investors are betting against the stock, which could lead to further price volatility and downward pressure on the share price.
-
Recent insider selling activity, including a sale of 1,758 shares by EVP Bryan Supran and previous sales by CEO Yvonne Greenstreet and other executives, may signal a lack of confidence among company leadership in the current stock price or a desire to diversify personal holdings, which could be interpreted negatively by the market.
-
Alnylam Pharmaceuticals, Inc. has a high price-to-earnings ratio of 42.20, which is significantly above the biotechnology sector average, indicating that the stock is priced for continued high growth and may be vulnerable to any disappointment in future earnings or revenue guidance, as seen in the recent cut to full-year revenue guidance due to slower-than-expected sales for AMVUTTRA.
| | View Today's Stock Pick |
|
| |
|
|
